Bilateral uveitis associated with fluoroquinolone therapy

Cutaneous and Ocular Toxicology

Volumn 31, Issue 2, 2012, Pages 111-116

  Hinkle, David M ^a   Dacey, Mark S ^c   Mandelcorn, Efrem ^d   Kalyani, Partho ^e   Mauro, John ^f   Bates, James H ^g   Soukasian, Sarkis H ^h   Holland, Gary N ^e   Foster, C Stephen ^a   Fraunfelder, Frederick T ^b   Davis, Janet L ⁱ   Fraunfelder, Frederick W ^b  

^a MERSI   (United States)

^b CASEY EYE INSTITUTE   (United States)

^c Margolis Vision   (United States)

^d Uptown Eye Specialists   (Canada)

^e JULES STEIN EYE INSTITUTE   (United States)

^f NEW YORK EYE AND EAR INFIRMARY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolones; immunology; uveitis

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; HLA B51 ANTIGEN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; RIFABUTIN;

ANTIBIOTIC THERAPY; BRONCHITIS; CASE STUDY; DATA BASE; DISEASE COURSE; DISEASE REGISTRY; FEVER; FOOD AND DRUG ADMINISTRATION; GENDER; HAPLOTYPE; HUMAN; IRIS DISEASE; LITERATURE; NEPHRITIS; NEUROLOGIST; OTITIS; PHARYNGITIS; PNEUMONIA; RETROSPECTIVE STUDY; REVIEW; SEPTICEMIA; SINUSITIS; SYSTEMIC DISEASE; URINARY TRACT INFECTION; UVEITIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OTITIS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEPSIS; URINARY TRACT INFECTIONS; UVEITIS; YOUNG ADULT;

EID: 84862101062     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.617024     Document Type: Review

References (20)

1. Owens RC Jr, Ambrose PG. Antimicrobial safety: Focus on fluoroquinolones. Clin Infec Dis 2005;41(suppl):S144-S157.
2. Physician's Desk Reference (PDR), 60th edn. Montvale, NJ: Thomson PDR, 2006, 2991-2998.
3. Fraunfelder FW, Fraunfelder FT. Diplopia and fluoroquinolones. Ophthalmology 2009;116:1814-1817.
4. Bringas Calvo R, Iglesias Cortiñas D. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol 2004;79:357-359.
5. Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, De Waard PW, Missotten TO, Martinez Ciriano JP et al. Uveitislike syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 2009;23:2260-2262.
6. Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 2010;24:1419; author reply 1419-1419; author reply 1420.
7. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994;10:93-102.
8. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259-268.
9. Moore B, Safani M, Keesey J. Possible exacerbation of myasthenia gravis by ciprofloxacin [letter]. Lancet 1988;1:882.
10. Motolese E, d'Aniello B, Addadbb G. Toxic optic neuropathy after administration of quinolone derivative. Boll Ocul 1990;69:1011-1013.
11. Pinar V, Gion N, Foster CS. Tubulointerstitial nephritis and uveitis syndrome. In: Foster CS, Vitale A (eds), Diagnosis and Treatment of Uveitis. WB Saunders: Philadelphia, PA, 2002.
12. Tugal-Tutkun I, Araz B, Taskapili M, Akova YA, Yalniz-Akkaya Z, Berker N et al. Bilateral acute depigmentation of the iris: Report of 26 new cases and four-year follow-up of two patients. Ophthalmology 2009;116:1552-7, 1557.e1.
13. Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol 2006;124:178-182.
14. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina (Philadelphia, Pa) 2006;26:187-190.
15. Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008;34:1451-1459.
16. Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33:63-68.
17. Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER. Intravitreal clearance of moxifloxacin. Trans Am Ophthalmol Soc 2005;103:76-81; discussion 81.
18. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005;50:364-388.
19. Desarnaulds AB, Borruat FX, Herbort CP, Spertini F. Multiple evanescent white dot syndrome: A genetic predisposition. Klin Monbl Augenheilkd. 1996;208:301-302.
20. Telander DG, Holland GN, Wax MB, Van Gelder RN. Rubeosis and anterior segment ischemia associated with systemic cryoglobulinemia. Am J Ophthalmol 2006;142:689-690.